Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Liability, Advertising Lawsuits Plague Biosimilars Market?

This article was originally published in Scrip

Executive Summary

While generic drug makers are shielded against failure-to-warn and design-defect lawsuits thanks to some rulings in recent years by the US Supreme Court – although that could change if an FDA proposal on updating labeling with safety information for those products goes into effect – that may not be the case for companies that make and market biosimilars, said Elaine Herrmann Blais, a partner and head of litigation at Goodwin Procter's Boston office.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC064355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel